Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are originally used for type 2 diabetes and obesity management, have shown the potential to be a promising class of medications currently under investigation for alcohol reduction. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.